

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application number		10/574,560		
				Filing date		1 February 2007		
				First Named Inventor		Serdar SEL et al		
				Art Unit		1635		
				Examiner name		Bowman, A		
				Attorney Docket Number		23593		
U.S. PATENTS								
Ex. Initials	Cite No.	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear		
	1	7355035		8 April 2008	D.G. ATKINS			
	2							
	3							
	4							
	5							
U.S. PATENT APPLICATION PUBLICATIONS								
Ex. Initials	Cite No.	Publication Number	Kind Code	Publication date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear		
	1							
	2							
	3							
FOREIGN PATENT DOCUMENTS								
Ex. Initials	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear	Tra ?
	1	WO 00/51621			8 Sept. 2000	Epigenesis Pharm		
	2	WO 01/11023			15 Feb. 2001	Johnson & Johnson		
	3							
	4							
NON-PATENT LITERATURE								
Ex. Initials	Cite No.	AUTHOR NAME, Article Title, Book Title, Date, Page(s), Vol/Iss. No., Publisher, City/Country						
	1	Santoro S W et al; A general purpose RNA-cleaving ...; Nat. Acad. Sci., Vol. 94, April 1997; pgs. 4262-4266						
	2	Sun L Q et al; Catalytic nucleic acids ...; Pharma. Review; Williams & Wilkins Inc.; Sept. 2000; pgs. 325-347						
	3	Imagawa S et al; Negative regulation of the erythropoietin ...; Blood, W.B. Saunders; Feb. 1997; pgs. 1430 - 1439						
EXAMINER SIGNATURE								
Examiner Signature					Date Considered			

14 January 2011

KF Ross PC
Customer Number 535
5683 Riverdale Ave. Box 900
Bronx (Riverdale), NY 10471
23593PTOSB81.WPD